Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial

Publication Type
Journal Article
Year of Publication
2020
Authors
Michelle J Groome; Lee Fairlie; Julie Morrison; Alan Fix; Anthonet Koen; Maysseb Masenya; Lisa Jose; Shabir A Madhi; Nicola page; Monica McNeal; Len Dally; Iksung Cho; Maureen Powert; Jorge Flores; Stanley Cryz
Secondary
Lancet Infect Dis
Date Published
04/2020
Keywords
p2-vp8; PATH VAC; Rotavirus Vaccines
Abstract
A monovalent, parenteral, subunit rotavirus vaccine was well tolerated and immunogenic in adults in the USA and in toddlers and infants in South Africa, but elicited poor responses against heterotypic rotavirus strains. We aimed to evaluate safety and immunogenicity of a trivalent vaccine formulation (P2-VP8-P[4],[6],[8]).